What is ResMed?
Sleep and respiratory care technology company with $5.146B of FY2025 revenue and enterprise healthcare scale.
- Category
- Sleep and respiratory care technology
- Headquarters
- San Diego, CA
- Founded
- 1989
- Employees
- 11,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: RMD; ~$37B market cap
What is ResMed?
ResMed is a public sleep and respiratory care technology company headquartered in San Diego, CA. It reported $5.146B of FY2025 revenue and operates at global enterprise scale.
ResMed operates in sleep and respiratory care technology with a portfolio spanning Sleep and breathing health devices, masks, accessories, and residential-care software. The company reported $5.146B of FY2025 revenue, employs about 11,000+, and trades as NYSE: RMD. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, ResMed is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, ResMed is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does ResMed offer?
ResMed offers healthcare products and services across Sleep and breathing health devices, masks, accessories, and residential-care software.
- CPAP and APAP devices· Sleep
- Masks and accessories· Consumables
- Ventilation devices· Respiratory
- Digital health platforms· Software
- AirView· Provider software
- myAir· Patient app
- SaaS for out-of-hospital care· Software
How does ResMed make money?
ResMed sells connected sleep and respiratory devices, masks, accessories, and software subscriptions for providers, payers, patients, and out-of-hospital care organizations.
ResMed sells connected sleep and respiratory devices, masks, accessories, and software subscriptions for providers, payers, patients, and out-of-hospital care organizations. In FY2025, that model produced $5.146B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is device-, mask-, accessory-, reimbursement-, durable-medical-equipment-, distributor-, and SaaS-subscription based; recurring mask replenishment and software seats complement device sales. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads ResMed?
ResMed is led by Mick Farrell, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Mick FarrellChairman and Chief Executive OfficerCEO since 2013Leads ResMed's connected sleep, respiratory, and SaaS strategy.
- Brett SandercockChief Financial OfficerCFO since 2006Finance leader through ResMed's global device and SaaS expansion.
- Lucile BlaisePresident, Sleep and Respiratory CareSenior executive leadershipCommercial leader for core device and mask growth.
- Raj SodhiPresident, SaaSSenior executive leadershipLeads residential-care software and digital health platforms.
How do you contact ResMed's leadership?
ResMed publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investorrelations@resmed.com) or official contact forms rather than guessed personal addresses.
investorrelations@resmed.com is a public investor/contact route; personal executive email format not verifiedSources:ResMed contactResMed leadership
How much funding has ResMed raised?
ResMed is a mature public company, not a venture-backed startup. It trades as NYSE: RMD, had an approximate ~$37B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
ResMed's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1989, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported $5.146B of FY2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: ResMed has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did ResMed get here?
ResMed grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1989Company foundedResMed commercializes sleep-apnea treatment technology.
- 1995IPOResMed becomes publicly traded.
- 2016Brightree acquiredResMed expands into SaaS for durable medical equipment and post-acute workflows.
- 2018MatrixCare acquiredResidential-care software becomes a larger pillar.
- 2025$5.146B revenueFiscal 2025 revenue grows 10%.
- 2026FY26 growth continuesResMed reports continued first-quarter fiscal 2026 growth.
Who are ResMed's competitors?
ResMed competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- PhilipsSleep and respiratory care device competitor.
- Fisher & Paykel HealthcareMasks, humidification, and respiratory-care competitor.
- Inspire Medical SystemsImplantable sleep-apnea therapy competitor.
- React HealthSleep and respiratory device competitor.
- AdaptHealthDME provider and channel partner/competitor in patient supply workflows.
ResMed — frequently asked questions
